The General Meeting is the corporate body that has the highest authority in Biotage. All shareholders may participate at the General Meetings.
The Annual General Meeting (the “AGM”) attends to such matters as the development of the Company’s business during the preceding fiscal year and resolutions are passed in a number of important items such as approving the Annual Report, disposition of the result of the year, dividends, discharge of the Board of Directors and the CEO, election of members of the Board of Directors and the auditors, fees and allocation of fees to the Board of Directors and the auditors, and guidelines for compensation of the executive management.
The notice for the AGM is published at the earliest six weeks prior to and no later than four weeks before the AGM.
A shareholder has the right to request that a certain item is made subject to the AGM. To ensure that the Company is able to amend such an item to the notice for the AGM, such request shall be with the Company no later than seven weeks prior to the AGM. The request to have an item addressed at the AGM shall be made to the Company’s Board of Directors at the address set out below:
Biotage AB
Attn. CLO
P.O. Box 8
SE-751 03 Uppsala
Sweden
The General Meeting does also resolve in such important matters as changes and amendments to the Articles of Association, share based incentive programs, issue of shares and derivatives of shares, authorization of the Board of Directors to resolve on the issue of shares and derivatives of shares, approval of issues of shares and derivatives shares that are resolved by the Board of Directors but conditioned to the approval of the General Meeting.
The Company may hold other General Meetings than the AGM. The notice for an extra ordinary General Meeting, were the subject is not the change of the Company’s Articles of Association, shall be published at the earliest six weeks prior to and not no later than two weeks before the General Meeting. If the subject of the General Meeting concerns a change of the Company’s Articles of Association, then the notice period for the AGM applies.
28 April 2021
Biotage is a Global Impact Tech Company committed to solving society’s problems. We offer workflow solutions and products to customers in Drug Discovery and Development, Analytical Testing and Water and Environmental Testing.
Biotage is contributing to sustainable science with the goal to make the world healthier, greener and cleaner – HumanKind Unlimited.
Our customers span a broad range of market segments including Pharmaceutical, Biotech, Contract Research and Contract Manufacturers as well as Clinical, Forensic and Academic laboratories in addition to organizations focused on Food safety, Clean water and Environmental sustainability.
Biotage is headquartered in Uppsala in Sweden and employs approx. 500 people worldwide. The Group had sales of SEK 1,101 million in 2019 and our products are sold in more than 70 countries. Biotage share (BIOT) is listed in the Mid Cap segment on the NASDAQ Stockholm.
Copyright © 2021 Biotage
Biotage är ett Globalt Impact Tech företag som är djupt engagerade i att lösa samhällsproblem. Vi erbjuder lösningar för kunders arbetsflöden inom Forskning och Tillverkning av Läkemedel, Analytisk Testning och Vatten- och Miljöanalyser.
Biotage bidrar till hållbar vetenskap och vi strävar efter att göra världen mer hälsosam, grönare och renare för mänskligheten – HumanKind Unlimited.
Våra kunder spänner över ett brett spektrum av marknadssegment från läkemedel, bioteknik, kontraktsforskning och kontraktstillverkning till kliniska, forensiska och akademiska laboratorier liksom organisationer som fokuserar på livsmedelssäkerhet, rent vatten och miljömässig hållbarhet.
Biotage har huvudkontor i Uppsala, Sverige, och har ca 500 anställda världen över.
Koncernen hade en försäljning på 1 101 miljoner kronor 2019 och våra produkter säljs i mer än 70 länder.
Biotage aktie (BIOT) är noterad på NASDAQ Stockholm, Mid Cap.
Copyright © 2020 Biotage
SEL-2EV
Two Channel, Extended Collection Bed, UV Detector